



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :

C12N 15/10, 5/10, 15/63, 15/85, A61K
35/14, 39/00 // C07K 14/725

A1

(11) International Publication Number:

WO 96/15238

(43) International Publication Date:

23 May 1996 (23.05.96)

(21) International Application Number:

PCT/GB95/02691

(22) International Filing Date:

16 November 1995 (16.11.95)

(30) Priority Data:

9423085.1

16 November 1994 (16.11.94)

GB

(71)(72) Applicant and Inventor: STRINGER, Bradley, Michael,
John [GB/GB]; 3 Caer Cady Close, Cyncoed, Cardiff CF2
6BS (GB).(74) Agents: PRICE, Vincent, Andrew et al.; Graham Watt & Co.,
Riverhead, Sevenoaks, Kent TN13 2BN (GB).(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH,
CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE,
KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN,
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT,
BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW,
SD, SZ, UG).

Published

*With international search report.**Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
amendments.*

(54) Title: TARGETED T LYMPHOCYTES

(57) Abstract

Targeted cytotoxic T lymphocytes have a TcR comprising heterologous α and β polypeptides, which heterologous polypeptides confer on the lymphocyte MHC Class I-restricted specificity for disease-causing target cells. The lymphocytes may be monovalent, having a single species of TcR conferring specificity for a single class of target cells. The lymphocytes find application as vaccines and in adoptive immunotherapy, e.g. cancer, AIDS or antiviral therapy.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

TARGETED T LYMPHOCYTES

The present invention relates to targeted cytotoxic T lymphocytes and their uses, and in particular to targeted
5 cytotoxic T lymphocytes having heterologous α and β T-cell antigen receptor polypeptides which confer MHC-restricted specificity for disease-causing target cells.

The immune system comprises a multitude of different cell
10 types and molecules distributed throughout the body. In healthy individuals, the immune system defends and protects against invading pathogens, parasites and cells which have become infected or cancerous.

15 The cellular basis for several fundamental properties of the immune system (including immunological memory, specificity and diversity of responses) is the lymphocyte. Lymphocytes fall into two classes: the B-lymphocyte (or B-cell), which is ultimately responsible
20 for generating humoral responses (mediated by soluble antibodies) and the T-lymphocyte (or T-cell), which is ultimately responsible for generating cell-mediated responses.

25 T-lymphocytes are further divided into inter alia

-2-

cytotoxic T lymphocytes (which identify and kill infected, aberrant or malignant target cells) and helper T lymphocytes (which stimulate, recruit and activate a broad range of cell-types involved in mounting an immune response).

T-lymphocytes recognize target cells via T cell receptors (hereinafter, TcRs). TcRs do not generally show binding to antigen alone. Rather, TcRs recognize antigen as part of a cell-surface glycoprotein complex encoded by class I or class II genes of the major histocompatibility complex (hereinafter referred to as the MHC Class I or MHC Class II). Cytotoxic T lymphocytes generally recognize antigens in association with MHC Class I, whereas helper T lymphocytes generally recognize antigens in association with MHC Class II.

As a result, T-lymphocyte target cell recognition is restricted to target cells capable of presenting antigen in association with particular host proteins (viz. the class I or class II MHC molecules). The primary role of the T-lymphocyte may therefore be viewed as the monitoring of cell surfaces in the body so that aberrant, infected or malignant cells can be identified (or detected, in the case of helper T cells) and ultimately

-3-

eliminated.

The T cell Receptor (TcR)

- 5 The TcR is a protein complex, one type of which includes two disulphide cross-linked polypeptide chains (the α and β chains) which are associated on the T lymphocyte cell surface with other molecules. The α and β chains of the TcR are sufficient to endow a T lymphocyte with both
10 antigen and MHC (of either Class I or II) specificity: only the α and β components of the TcR are therefore required to define completely the dual (i.e. MHC and antigen) T lymphocyte specificity.
- 15 The α and β chains comprise constant and variable regions which are homologous to immunoglobulin V and C regions, and the corresponding structural genes undergo DNA arrangements reminiscent of those of the immunoglobulin genes. Indeed, the structural repertoire
20 of immunoglobulins and TcRs are similar (about 10^{12} per individual).

The genes encoding the α and β chains of the TcR have been cloned and sequenced (see e.g. Robertson (1985),
25 Nature 317, 768-771). Moreover, TcR α and β -chain genes

-4-

have been transferred from one T cell to another to generate a T cell clone of different specificity (see e.g. Dembic et al., 1986, Nature 320, pp. 232-238).

5 TcRs are clonally distributed: the TcRs of each T lymphocyte are specific for just one antigenic determinant (though there may be hundreds of thousands of the same species of TcR on each cell). Thus, each T lymphocyte is normally monovalent with respect to TcR-
10 mediated binding.

The α and β chains are associated with several other molecules, including proteins of the CD3 complex and associated zeta and eta peptides. The TcR-CD3 complex
15 transduces a signal from the TcR to the interior of the T lymphocyte when it recognizes the appropriate peptide-MHC complex, thus contributing to T-cell activation.

Aberrant gene expression, disease and the T cell response

20 The health of an individual depends on the co-ordinated and tightly-regulated expression of many thousands of different genes. Aberration or alteration of gene expression, even if subtle, can therefore give rise to a
25 plethora of different diseases, including cancers, AIDS

-5-

and various autoimmune diseases.

Many different factors may induce aberrant gene expression. For example, the expression of endogenous
5 genes or the structure of the proteins encoded thereby may be altered by mutation. Such mutations may be spontaneous, but are often induced by carcinogens present in the environment. Alternatively, the introduction of
exogenous genetic material into cells of the individual
10 (for example as a result of viral infection) may result in the disruption of gene expression patterns, the activation of normally silent genes and/or the synthesis of foreign (e.g. viral) proteins.

15 One important example of the consequences of induced aberrations in gene expression is that of tumour formation. Tumour formation characterizes most cancers, and the tumours arise as a consequence of the structural alteration or overexpression of endogenous proteins
20 attendant on the mutation of oncogenes and tumour suppressor genes in somatic cells. For example, in certain types of breast cancer tumour formation arises from amplification and overexpression of the HER-2/neu protooncogene.

25

-6-

Apart from the onset of disease at the organismal level, another phenotypic consequence of aberrant gene expression may be the production of neoantigens. As used herein, the term "neoantigen" is intended to cover not
5 only new antigens arising from mutant or foreign amino acid sequences, but also "new" antigens arising from the expression of normally silent wild-type genes, or the overexpression of normally relatively weakly-expressed wild-type genes.

10

The production of neoantigens may give rise to alterations in cell surface antigens, which alterations can in turn induce an immune response. For example, antibodies directed against oncogene products have been
15 found in the serum of tumour patients and cytotoxic T lymphocytes which recognize and eliminate tumour cells have been demonstrated in a number of model systems.

Alterations in cell surface antigens capable of
20 triggering a cytotoxic T lymphocyte response may arise following intracellular processing of the mutant, foreign or overexpressed proteins to produce peptide fragments which may be displayed at the cell-surface as part of a peptide-MHC Class I complex capable of recognition by
25 cytotoxic T lymphocytes. In this way, aberrant cells may

-7-

be recognized and eliminated by T lymphocytes.

In addition to alterations in cell surface antigens, protein overexpression, foreign (e.g. viral-derived) or mutant protein production may ultimately result in the appearance of exogenous neoantigens (e.g. virus particles or fragments). These may be recognized by membrane-bound immunoglobulins on the surface of B-lymphocytes, internalized, processed and subsequently presented as helper T-cell antigens as a complex with MHC class II molecules at the surface of the B-cell. A B-cell which is presenting antigen in this way can be recognized by a helper T-cell via a specific TcR-peptide-MHC Class II interaction and stimulated to develop into a plasma cell secreting large quantities of soluble antibodies specific for the exogenous antigen. In this way the helper T lymphocyte may stimulate a humoral immune response and indirectly activate a wide range of immune cell-types.

There are many reports of tumour-specific or tumour-associated neoantigens. For example, overexpression of the ERBB2 receptor is associated with many human breast and ovarian cancers and also results in the appearance of ERBB2-derived neoantigens at the cell surface. In colon cancer, the adenomatosis polyposis coli gene (APC)

-8-

usually undergoes early mutation. Although the mutation often simply results in the introduction of a stop codon (which terminates translation resulting in the production of truncated APC protein), in many cases the mutation is a frameshift which results in the production of new protein sequences and potentially unique antigens. Once processed intracellularly and bound to the MHC proteins, such antigens may be presented at the cell surface and recognized by T lymphocytes.

10

In many other cases the structural alteration or overexpression of endogenous proteins would be expected to result in alterations in the intracellular processing of these proteins and the presentation of neoantigens in association with MHC proteins on the cell surface.

15

Despite the above-described immunogenic consequences of aberrant gene expression, the natural immune response mounted to combat infected, aberrant or malignant cells is often inadequate. Although the reasons for this failure are not fully understood, it is thought that neoantigens are often treated by the immune system as tissue-specific antigens and so tolerated in the same way. Moreover, neoantigens usually constitute only a minor source of peptides for MHC-class I directed

20

25

-9-

processing, and so neoantigen processing and presentation may be extremely inefficient. Finally, immunogenicity appears to be determined in part by the tissue type in which the neoantigen is expressed, and so it seems that
5 tolerance may be greater (and/or processing and presentation less efficient) in certain tissue types.

Several approaches have been developed to generate more effective immune responses against aberrant, infected or
10 malignant cellular targets. For example, it has been proposed to use antigens from malignant cells as vaccines to induce tumour-specific cell-mediated immunity.

More recently, adoptive immunotherapy has been proposed
15 as a mode of cancer treatment. This mode of therapy is based on the transfer of immune cells with antitumour activity into cancer patients. The immune cells used are derived from the cancer patient, cultured, and reintroduced after expansion in tissue culture.

20

The cells used in adoptive immunotherapy include lymphokine-activated killer cells, tumour-infiltrating lymphocytes and in vitro sensitized lymphocytes derived from cytotoxic T lymphocytes.

25

-10-

Lymphokine-activated killer cells are cytolytic cells which react with a broad spectrum of target cells. They are not MHC-restricted and lyse both tumour and normal cells. Therapies based on the use of these cells
5 therefore suffer the disadvantage that tumour cell killing is accompanied with significant damage to normal tissue.

Tumour-infiltrating lymphocytes are derived from tumour
10 tissues. They are more potent than lymphokine-activated killer cells and relatively specific for their tumours of origin, thus avoiding the problems arising from non-selective ablation of normal tissue associated with the use of lymphokine-activated killer cells. However, the
15 availability of these cells is severely restricted, being dependent on their natural occurrence in tumour tissues and their expansion in vitro. Thus, therapies based on the use of these cells would be available in only a fraction of cases.

20

While each of the adoptive immunotherapies discussed above have been shown to be capable of mediating tumour regression to some extent, therapeutic responses have been observed in only a few cases (and even then were
25 exhibited in only a fraction of the patients treated).

-11-

It has been proposed (Moritz et al. (1994), PNAS, 91, pp. 4318-4322) to improve the efficacy of lymphocyte-mediated tumour therapy by in vitro manipulation of the recognition specificity of cytotoxic T lymphocytes to

5 endow them with a defined tumour cell specificity.

Moritz et al. approached this problem by circumventing the TcR-based (and therefore MHC-restricted) specificity to create a wholly synthetic "pseudoreceptor" comprising a single chain antibody (to confer binding specificity)

10 joined (via a hinge) to a TcR-complex zeta chain.

Cytotoxic T cells bearing the synthetic pseudoreceptor were found to exhibit MHC-independent recognition with a specificity conferred by the antibody component.

15 However, the use of a wholly synthetic pseudoreceptor appears to lead to inefficient signal transduction and a reduction in T cell activity. Moreover, since the recognition specificity of the targeted cytotoxic T lymphocytes described in Moritz et al. is MHC-

20 independent, the efficiency of cell-surface scanning by the lymphocytes is likely to be impaired. Finally, the synthetic pseudoreceptor might itself elicit undesirable immune responses.

25 It is an object of the present invention to provide

-12-

alternative targeted T lymphocytes for use e.g. in adoptive immunotherapy which do not express wholly synthetic pseudoreceptors, but are instead targeted via TcRs which are essentially similar in structure to normal TcRs. The normal signal transduction pathway is therefore preserved and the risks of undesirable immune responses minimized. Moreover, the targeted T cells of the invention are MHC-restricted so that they can efficiently scan cell surfaces for aberrant antigens.

10

Accordingly, the present invention provides a targeted cytotoxic T lymphocyte having a TcR comprising heterologous α and β polypeptides, which heterologous polypeptides confer on the lymphocyte MHC Class I-restricted specificity for disease-causing target cells.

15

As used herein the term "heterologous α and β TcR polypeptides" is intended to denote α and β TcR chains which are not normally expressed in the T-cell. In one embodiment, the heterologous TcR polypeptides are chimaeras or synthetic molecules derived from the expression of recombinant or wholly synthetic DNA. In other embodiments the heterologous TcR polypeptides are derived, directly or indirectly (e.g. via a TcR gene library), from another T-cell. The other T-cell may

20

25

-13-

itself be derived from any source, so long as it expresses TcR components of the required specificity. For example, the other T-cell may be from the same species (or even the same individual), or from a different
5 species. It may also be a T-cell hybridoma.

The specificity for disease-causing target cells need not be absolute. For the purposes of the invention, it is sufficient if the specificity is such that any attendant
10 autoimmune-type ablation of normal or non-diseased tissue can be tolerated by the patient.

For example, in circumstances where the disease-causing cells are all members of a particular tissue which is
15 itself dispensable, it is sufficient if the targeted T lymphocyte is effectively specific for that tissue. This might be the case where the targeted disease-causing cells are malignant prostate tumour cells - here it is sufficient if the cytotoxic T-cells are targeted with
20 sufficient specificity to ablate both normal and cancerous prostate tissue (while other tissues are unaffected or ablated to a lesser and tolerable extent). Another example is melanoma - although some melanocyte-specific antigens also appear in certain cells of the
25 retina, brain and inner ear, these latter cells appear to

-14-

be less sensitive to immunotherapy based on the melanocyte-specific antigen.

Another situation where absolute specificity may not be required arises where the normal tissue counterpart of a particular tumour express MHC Class I at extremely low levels, thereby shielding it from cytotoxic T-cell attack.

10 The term "disease-causing cell" is used herein in a broad sense to denote not only cells which are directly involved in disease (for example tumour cells or autoimmune cells) but also cells which are associated with the progression of disease or which help promote or
15 maintain the disease state (for example virally-infected cells). It therefore covers any cell which is aberrant and deleterious to the health of the individual in any way.

20 The targeted cytotoxic T lymphocyte of the invention is preferably recombinant, being for example transduced with a viral vector.

The targeted cytotoxic T lymphocyte of the invention is
25 preferably monovalent with respect to the targeted cells,

-15-

having a single species of TcR conferring MHC Class I-restricted specificity for a single class of target cells. Such monovalent lymphocytes may be generated e.g. by replacing (rather than supplementing) the resident (or
5 endogenous) α and β chain genes with heterologous α and β chains conferring the required specificity.

Monovalent lymphocytes of the invention may also be generated by downregulating or blocking the expression of
10 the endogenous TcR by any of the wide range of techniques available. For example, targeted insertional mutagenesis may be used to disrupt the endogenous TcR genes.

The use of monovalent lymphocytes avoids problems arising
15 from the formation of mismatched (and therefore inactive and/or non-selective) α and β dimers. The formation of such inactive heterodimers reduces the effective cell surface density of the TcRs which may impair or prevent target cell recognition and lysis. By ensuring
20 monovalency of the lymphocytes of the invention, the cell surface density of the TcRs is optimized.

However, in some circumstances it may be preferable or convenient to provide polyvalent cytotoxic T lymphocytes
25 which have two or more distinct species of TcR which

-16-

together confer MHC Class I-restricted specificity for two or more classes of target cells. Such polyvalent lymphocytes may be generated e.g. by supplementing (rather than replacing) the resident α and β chains with one or more pairs of heterologous α and β chains conferring the required specificity. The polyvalent targeted cytotoxic T lymphocytes of the invention may find particular application in circumstances where it is necessary to target two or more distinct classes of target cells.

Where the targeted cytotoxic T lymphocyte of the invention is polyvalent, the heterologous α and β TcR polypeptides are preferably provided as a single fusion polypeptide. This prevents the formation of mismatched (and therefore inactive and/or non-selective) α and β dimers, so avoiding the problems associated with reduced effective cell surface TcR density described above.

The target cells preferably comprise tumour cells, immune cells contributing to an autoimmune response and/or cells infected with a pathogen (and in particular, virus-infected cells). In a particularly preferred embodiment the target cells comprise HIV-infected lymphocytes. Other viral infections include hepatitis (e.g. hepatitis B,C

-17-

-and NANB) and virally-induced Burkitt's lymphoma

The heterologous α and β TcR polypeptides may be chimaeric, and may for example comprise an immunoglobulin variable domain or fragment thereof. Such chimaeric TcRs exploit the close structural similarities between the constant and variable regions of the α and β chains of the TcR and immunoglobulin V and C regions. The use of such chimaeric α and β TcR polypeptides may be particularly convenient where an immunoglobulin exhibiting the required specificity is available or readily obtainable (for example by raising antibodies to known or predicted T-cell antigens).

In another aspect, the invention also contemplates a method for producing the targeted cytotoxic T lymphocyte of the invention, the method comprising the steps of: (a) providing a vector comprising DNA (e.g. DNA derived from a donor cytotoxic T lymphocyte) encoding α and β TcR polypeptides specific for disease-causing target cells, and (b) transfecting a recipient cytotoxic T lymphocyte with the vector of step (a) to produce a recombinant cytotoxic T lymphocyte having DNA encoding α and β TcR polypeptides specific for disease-causing target cells, whereby the recombinant cytotoxic T lymphocyte of step

-18-

- (b) expresses the DNA encoding α and β TcR polypeptides to endow the lymphocyte with MHC-Class I restricted specificity and thereby target it to the target cells.
- 5 The vector of step (a) may be provided by cloning, assembling or synthesising (e.g. by solid phase oligonucleotide synthesis) DNA encoding α and β TcR polypeptides specific for disease-causing target cells. Preferably, the DNA encoding the α and β TcR
- 10 polypeptides is cloned by: (a) obtaining a sample of donor T lymphocytes, e.g. from a blood bank, blood sample or tumour biopsy; (b) enriching the sample of donor T lymphocytes for cytotoxic T lymphocytes having specificity for disease-causing target cells, e.g. by
- 15 specifically induced proliferation and/or specific clonal expansion; (c) extracting chromosomal DNA from the donor cytotoxic T lymphocytes; and (d) isolating DNA encoding the α and β TcR polypeptides, e.g. by primer-specific PCR amplification.
- 20
- The vector may be introduced into the recipient cytotoxic T lymphocyte by any suitable method. Many different methods are known to those skilled in the art, including transfection by electroporation, protoplast fusion or
- 25 viral (e.g. retroviral) transfection.

-19-

The invention also relates in a further aspect to a vector for use in the method of the invention, which vector comprises DNA encoding α and β TcR polypeptides specific for a disease-causing cell. The DNA of the
5 vector may preferably be operably linked to an expression element or elements to provide for expression of the TcR polypeptides at suitable levels. Any of a wide variety of expression elements may be used and the element(s) may take any form so long as they can (under at least some
10 circumstances) be made to direct and/or control the expression of the genes with which they are operably coupled. The expression element or elements may for example comprise transcriptional and/or translational elements, and include promoters, ribosome binding sites,
15 enhancers and regulatory sites including activator and repressor (operator) sites. By way of example only, the expression elements for use in the invention may be selected from those naturally associated with the α and/or β TcR peptide genes.

20 Conveniently, the vector of the invention is a viral vector, being for example based on simian virus 40, adenoviruses (e.g. human adenoviruses), retroviruses, and papillomavirus.

25

-20-

The vector may further comprise; (a) a positive selectable marker, the marker for example being selected from neomycin phosphotransferase, hygromycin phosphotransferase, xanthineguanine phosphoribosyl transferase, the Herpes simplex virus type 1 thymidine kinase, adenine phosphoribosyltransferase and hypoxanthine phosphoribosyltransferase and/or (b) a negative selectable marker, the marker for example being selected from Herpes simplex virus type 1 thymidine kinase, adenine phosphoribosyltransferase, hygromycin phosphotransferase and hypoxanthine phosphoribosyltransferase.

The use of a positive selectable marker facilitates the selection and/or identification of transfected T lymphocytes, whereas the presence of a negative selectable marker permits the subsequent elimination of the transfected T cells either in vivo or in vitro (for example if undesirable side effects arise).

The methods of plasmid preparation so as to produce constructs to allow the transcription and translation of e.g. the α and β units in mammalian cells, and in particular, in the engineered cytotoxic T-lymphocytes, are well known to the man skilled in the art.

-21-

A particularly advantageous vector expresses both the α and β chains under the control of a single promoter.

Particularly preferred are promoters specific for T-cell and/or T-cell precursor/progenitor cell expression, and

5 the constructs may be separated by a poliovirus derived internal ribosomal entry site (IRES). The IRES allows two separate genetic elements to be expressed under the control of the same promoter/enhancer element placed at the 5' end of the sequence.

10

The vector may advantageously be a retroviral vector.

Retroviral transduction of mammalian cells is very efficient and can be used to transduce human cells with genes such as the α and β chains of a selected T-cell

15 receptor. The retroviral vector preferably has a specific 3' LTR deletion. Upon transduction with the vector of the cell to be engineered, and the vector's reverse transcription to form proviral DNA for subsequent incorporation into the hosts genome, the 5' LTR

20 promoter/enhancer element activity would be lost. This would allow expression to be placed under the control of selected promoters, thus permitting cytotoxic T-cell-specific expression (Yu SF et al 1986 PNAS USA 83 3194).

If vector size constraints are too limited in such a
25 retroviral vector, however, alternative vectors such as

-22-

adenoviral vectors could also be considered.

The targeted cytotoxic T lymphocytes and vectors of the invention find application in various forms of therapy, and in particular in adoptive immunotherapy. The lymphocytes and vectors are particularly useful in adoptive immunotherapy comprising the steps of; (a) removing cytotoxic T-lymphocytes from a patient and optionally selectively expanding them in tissue culture, (b) transfecting the cytotoxic T lymphocytes removed in step (a) with the vector of the invention to produce targeted cytotoxic T lymphocytes, and (c) reintroducing the targeted cytotoxic T lymphocytes of step (b) into the patient.

In the method described above, the T-lymphocytes used in the adoptive immunotherapy are autologous. This has particular advantages, because it ensures that the T-lymphocytes have the appropriate costimulatory and adhesion factors necessary for efficient recognition of target cells after reintroduction into the patient.

The therapy may be applied to cancer patients, AIDS patients, individuals suffering from an autoimmune disease or immunosuppressed individuals (for example

-23-

individuals bearing a transplanted organ) suffering an opportunistic infection.

The targeted cytotoxic T lymphocytes and vectors of the invention also find application as vaccines, e.g. for prophylactic use in individuals at high risk of disease. Examples of such high risk individuals include individuals predisposed by genetic or environmental factors to disease (e.g. cancer, AIDS or hepatitis). For example, the T-lymphocytes of the present invention could be used to provide immunity against AIDS of the type disclosed by Rowland-Jones et al. (1995), Nature Medecine, Vol. 1 (1), pages 59-64.

The invention will now be described in more detail by way of specific examples of proposed protocols which are believed to be practicable (with or without modification). These examples are not intended to be taken as limiting in any way.

Example 1: TcR Cloning

Cloning of T cell receptors has historically relied on the formation of cDNA libraries from the T cell carrying the receptor of interest. This has meant that for each T

-24-

cell receptor a new cDNA library has had to be made from the appropriate clonal cell line, which is a time consuming process.

- 5 However, between the genes of the two subunits of the T cell receptor, α and β , there are regions of sequence identity. These are known as the constant regions and are found in every α and β subunit gene. The sequences for these regions can be found from published data of
10 cloned T cell receptor subunits, and by comparing these it is possible to identify constant regions of sequence identity. Although these regions are called constant regions, analysis has shown that there is some variation between constant regions that have so far been cloned.
15 However, small regions of consistent sequences can be identified within a receptor subunit.

Using these regions it is possible to clone the full length α and β subunit transcripts by a method known as
20 inverse polymerase chain reaction (PCR) described by Ochman et al (Genetics (1988) 120: 621-623). This method relies on the ability of cDNA, derived from mRNA, to be circularised and using PCR primers designed against the known sequence of the transcript, amplify the whole cDNA
25 by chain elongation across the uncharacterised region of

-25-

the circularised DNA. However the resulting PCR products do not give the sequence of interest in the correct orientation, and it is therefore necessary to clone the PCR products to sequence them. Using the sequence data it is possible to visualise the sequence in the correct orientation and design normal PCR primers to amplify the full length cDNA in the correct orientation. These cDNA clones can then be cloned into expression vectors for further manipulation.

10

Since the inverse primers have been designed against a constant region, the same methodology and primers can be used for different T cell clones. This significantly reduces the cell number requirements and increases the speed and efficiency of TcR cloning.

15

The method can be summarized as follows (see Figures 1 to 3):

- 20 1) Total RNA is isolated from the T cell clone of interest using Trizol reagent.
- 2) cDNA is produced from the total RNA by reverse transcription using an Oligo dT as the primer for transcription.
- 25 3) Second strand synthesis is achieved by DNA

-26-

polymerase 1 in the presence of RNase H to create nicks and gaps in the hybridised mRNA strand, which provides 3'-OH priming sites for DNA synthesis.

5 4) Circularisation is performed with T4DNA ligase in a dilute DNA concentration that favours the formation of monomeric circles.

5) Linear cDNA is then removed by treatment with exonuclease III.

10 6) Using the resulting closed circular cDNA, the transcripts of interest are amplified by inverse PCR. The inverse primers are designed in such a way as to initially replicate the cDNA in opposite directions (as shown on Figure 1) giving linear products. These products then replicate as expected with normal PCR methodology.

15 7) The PCR products are separated on an agarose gel and several of the largest bands are excised from the gel and purified. The purified products are then used in a further PCR reaction. However, as a control, normal PCR primers designed to amplify a short length of the constant region of one of the T cell receptor subunits, are used. As the fragments obtained from the inverse PCR will contain constant regions, if they are truly T cell receptor subunit transcripts, normal PCR using these primers will

20

25

-27-

amplify short fragments which can be visualised on an agarose gel. Fragments which did not give normal PCR products when amplified using the appropriate normal primers do not represent clones of interest and are discarded.

8) The remaining fragments can be cloned into the TA vector (available from Invitrogen) which is a plasmid vector which relies on the 3' adenylation sites created during each round of replication by Taq polymerase, to incorporate the PCR product. Competent bacteria are then transformed with the resulting plasmids, and transformants selected by ampicillin resistance. Plasmids with inserts have a disrupted lac Z gene and therefore appear white when plated on nutrient agar containing X-gal.

9) Confirmatory digests are carried out on mini-preps of plasmid DNA from the selected clones. Selected clones are then expanded and large scale plasmid preps are made for automated sequencing.

10) Once the sequence data has been obtained it is possible to distinguish the correct orientation of the transcript by identifying the start codon ATG (see Figure 2 for more explicit explanation). Using this data it is then possible to design PCR primers to amplify the whole transcript from the original

-28-

linear cDNA preparation from the T cell clone.

These can then be cloned into a variety of vectors, including eukaryotic expression vectors.

- 5 It is possible to use this methodology for a limitless number of T cell receptor subunits, providing the appropriate T cell clones are available, without the need for designing new primers (except for the amplification of the full length transcripts at the end of the
10 procedure). In addition the whole procedure can be carried out in a matter of days, as opposed to weeks in the case of cDNA library generation.

15 Example 2: Construction of cytotoxic T cells targeted to the MAGE-1 melanoma antigen

Cytotoxic T-lymphocytes recognizing the MAGE-1 gene product MZ2-E (see e.g. Chen et al. (1994), PNAS 91, pp 1004-1008; Van den Eynde et al. (1989), Int. J. Cancer, 44, pp 634-640; van der Bruggen et al. (1991), Science, 254, pp. 1643-1647; Traversari et al. (1992), Immunogenetics, 35, pp. 145-152; Traversari et al. (1992), J. Exp. Med. 176, pp. 1453-1457) were collected and their DNA extracted.

-29-

A complementary DNA library was constructed from the extracted DNA using a lambda gt11 vector. Complementary DNA (cDNA) clones encoding the α and β chains were then isolated using α and β chain constant-region

5 hybridization probes described in e.g. Dembic et al. (1985) Nature 314, pp. 271-273 and Snodgrass et al. (1985) Nature 315, pp. 232-233. The procedure used was similar to that described in Dembic et al. (1986) Nature, 320, pp. 232-238.

10

The genes for both α and β chains were then cloned into a cosmid vector in the same transcriptional orientation, together with the neomycin-resistance gene as a positive selection marker. Appropriate expression elements were

15 functionally coupled to the α and β coding sequences to ensure efficient expression.

The cosmid vector containing the α and β chains was then transferred by protoplast fusion into a suitable

20 recipient cytolytic T cell hybridoma to yield a recombinant T-cell hybridoma having specificity for the MAGE-1 gene product.

Those skilled in the art will realize that the above

25 described method can be readily adapted to the recovery

-30-

and transfer of other TcRs, and can be applied with appropriate modifications to any recipient cytotoxic T-cell population.

5 Example 3: Generation of Human T-lymphocytes genetically engineered to express cytotoxic activity against cells expressing the influenza (Flu) virus.

Human whole peripheral blood mononuclear cells (PBMC),
10 derived from a class 1 MCH HLA-A2 blood donor, were prepared and cultured in-vitro in standard medium in the presence of Flu peptides known to be presented in a HLA-A2 restricted fashion. Thus, antigen presenting cells were formed.

15 Alternatively, antigen presenting cells can be formed by the addition of peptide to a population of dendritic cells isolated from a HLA-A2 restricted donor.

20 After 24 hours incubation with peptide, the PBMC's were added to CD4/CD8 cells derived from a recently influenza immunized human donor, also of the HLA-A2 class 1 MHC restricted idotype. The CD4/CD8 cell population derived from the immunized donor was plated in limiting dilution
25 (100 down to 1 cell) in microtitre plates and left in the

-31-

presence of the presenting cells for 10-14 days with appropriate medium changes. The plates were then screened for expanding colonies of T-lymphocytes which represented activated CD4/CD8 cells capable of
5 recognizing the antigen presenting cells and being cytotoxic to them.

These expanding colonies of activated T-lymphocytes, capable of recognising influenza antigen when presented
10 by cells in a class 1 MHC restricted fashion, were then cloned and used to prepare complete T-cell receptor α and β chain sequences as described in Example 1.
Alternatively, other methods of producing and isolating the α and β cDNA known to the man skilled in the art can
15 be employed.

Once isolated, the cDNA of the α and β chains were then used to engineer T-cells derived from a non-immune class 1 MHC HLA-A2 donor. This conferred to the genetically
20 engineered T-cells the ability to recognize influenza infected cells in a class 1 restricted fashion and mediate cytotoxicity as determined by chromium release assay.

-32-

Example 4: Generation of human T-lymphocytes genetically engineered to express cytotoxic activity against cells expressing a member of the ras oncogene family.

- 5 Human whole peripheral blood mononuclear cells (PMBC), derived from a class 1 MHC HLA-A2 blood donor, were prepared and cultured in-vitro in standard medium in the presence of Harvey ras or Kirsten ras or N-ras oncogene peptides known to be presented in a HLA-A2 restricted
10 fashion. Thus, antigen presenting cells were formed.

Alternatively, antigen presenting cells can be formed by the addition of the said peptide(s) to a population of dendritic cells isolated from a HLA-A2 restricted donor.

15

- After 24 hours incubation with peptide the PBMC's were added to CD4/CD8 cells derived from a series of human donors, also of the HLA-A2 class 1 MHC restricted
15 idotype. CD4/CD8 cell populations derived from the donors were plated in limiting dilution (100 down to 1
20 cell) in microtite plates and left in the presence of the presenting cells for 10-14 days with appropriate medium changes. The plates were then screened for expanding colonies of T-lymphocytes which represented activated
25 CD4/CD8 cells capable of recognizing the antigen

-33-

presenting cells and being cytotoxic to them.

These expanding colonies of activated T-lymphocytes, capable of recognising ras oncogene antigen when presented by cells in a class 1 MHC restricted fashion, were then cloned and used to prepare complete T-cell receptor α and β chain sequences as described earlier.

Once isolated, the cDNA of the α and β chains relating to recognition of either the Harvey ras or Kirsten ras of N-ras oncogene peptides was then used to engineer T-cells derived from a non-immune class 1 MHC HLA-A2 donor. This conferred to the genetically engineered T-cells the ability to recognize ras oncogene activation in cells in a class 1 restricted fashion and provided cell mediated cytotoxicity to such cells as determined by chromium release assay.

Example 5 - Generation of human T-lymphocytes genetically engineered to express cytotoxic activity against cells expressing HIV peptides.

Human whole peripheral blood mononuclear cells (PBMC), derived from a class 1 MHC HLA-B35 blood donor, were prepared and cultured in-vitro in standard medium in the

-34-

presence of HIV peptides known to be presented in a HLA-B35 restricted fashion. Thus, antigen presenting cells were formed.

- 5 Alternatively, antigen presenting cells can be formed by the addition of peptide to a population of dendritic cells isolated from a HLA-B35 restricted donor.

After 24 hours incubation with peptide, the PBMC's were
10 added to CD4/CD8 cells derived from human donor with potential HIV immunity, also of the HLA-B35 class 1 MHC restricted idotype. The CD4/CD8 cell population derived from the potentially immune donor was plated in limiting
15 left in the presence of the presenting cells for 10-14 days with appropriate medium changes. The plates were then screened for expanding colonies of T-lymphocytes which represented activated CD4/CD8 cells capable of
20 recognizing the antigen presenting cells and those which were cytotoxic to them.

These expanding colonies of activated T-lymphocytes, capable of recognising HLA-B35 processed HIV antigen when presented by cells in a class 1 MHC restricted fashion,
25 were then cloned and used to prepare complete T-cell

-35-

receptor α and β chain sequences as described earlier, or by alternative methods of producing and isolating the α and β cDNA known to the man skilled in the art.

- 5 Once isolated, the cDNA of the α and β chains was then used to engineer T-cells derived from a non-immune class 1 MHC HLA-B35 donor. This conferred to the genetically engineered T-cells, recognition of HIV infected cells in a class 1 MHC restricted fashion. Cell mediated
10 cytotoxicity by these engineered cells was shown by chromium release assay.

-36-

CLAIMS:

1. A targeted cytotoxic T lymphocyte having a TcR comprising heterologous α and β polypeptides, which
5 heterologous polypeptides confer on the lymphocyte MHC Class I-restricted specificity for disease-causing target cells.
2. The targeted cytotoxic T lymphocyte of claim 1 which
10 is recombinant, e.g. being transduced with a viral vector.
3. The targeted cytotoxic T lymphocyte of claim 1 or claim 2 which is monovalent, having a single species of
15 TcR conferring MHC Class I-restricted specificity for a single class of target cells.
4. The targeted cytotoxic T lymphocyte of claim 1 or claim 2 which is polyvalent, having two or more distinct
20 species of TcR which together confer MHC Class I-restricted specificity for two or more classes of target cells.
5. The targeted cytotoxic T lymphocyte of any one of the
25 preceding claims wherein the target cells comprise tumour

-37-

cells, immune cells contributing to an autoimmune response and/or cells infected with a pathogen.

6. The targeted cytotoxic T lymphocyte of claim 5 wherein
5 the target cells comprise human melanoma cells and the heterologous α and β polypeptides confer specificity for; (a) the MAGE-1 tumour antigen, (b) the MAGE-3 tumour antigen, (c) the MART 1/Aa tumour antigen, (d) the gp100 tumour antigen and/or (e) the tyrosinase tumour antigen.

10

7. The targeted cytotoxic T lymphocyte of claim 5 wherein the pathogen is a virus.

8. The targeted cytotoxic T lymphocyte of claim 7
15 wherein the target cells comprise HIV-infected lymphocytes.

9. The targeted cytotoxic T lymphocyte of any one of the preceding claims wherein the heterologous α and β TcR
20 polypeptides are provided as a single fusion polypeptide.

10. The targeted cytotoxic T lymphocyte of any one of the preceding claims wherein the heterologous α and β TcR polypeptides are chimaeric, for example comprising an
25 immunoglobulin variable domain or fragment thereof.

-38-

11. A method for producing the targeted cytotoxic T lymphocyte of any one of the preceding claims, the method comprising the steps of:

5 (a) providing a vector comprising DNA (e.g. DNA derived from a donor cytotoxic T lymphocyte) encoding α and β TcR polypeptides specific for disease-causing target cells, and

10 (b) transfecting a recipient cytotoxic T lymphocyte with the vector of step (a) to produce a recombinant cytotoxic T lymphocyte having DNA encoding α and β TcR polypeptides specific for disease-causing target cells,

15 whereby the recombinant cytotoxic T lymphocyte of step (b) expresses the DNA encoding α and β TcR polypeptides to endow the lymphocyte with MHC-Class I restricted specificity and thereby target it to the target cells.

20 12. The method of claim 11 wherein the vector of step (a) is provided by cloning, assembling or synthesising (e.g. by solid phase oligonucleotide synthesis) DNA encoding α and β TcR polypeptides specific for disease-
25 causing target cells.

-39-

13. The method of claim 12 wherein the DNA encoding the α and β TcR polypeptides is cloned by:

5 (a) obtaining a sample of donor T lymphocytes, e.g. from a blood bank, blood sample or tumour biopsy;

10 (b) enriching the sample of donor T lymphocytes for cytotoxic T lymphocytes having specificity for disease-causing target cells, e.g. by specifically induced proliferation and/or specific clonal expansion;

15 (c) extracting chromosomal DNA from the donor cytotoxic T lymphocytes; and

(d) isolating DNA encoding the α and β TcR polypeptides, e.g. by primer-specific PCR amplification.

20 14. The method of any one of claims 11 to 13 wherein the vector is transfected into the recipient cytotoxic T lymphocyte by electroporation, protoplast fusion or viral (e.g. retroviral) transfection.

25 15. A targeted cytotoxic T lymphocyte producible by the

-40-

method of any one of claims 11 to 14.

16. A vector for use in the method of any one of claims 11 to 14 comprising DNA encoding α and β TcR

5 polypeptides specific for a disease-causing cell, the DNA for example being operably linked to an expression element or elements, the expression element or elements being selected for example from transcriptional and/or translational elements, promoters, ribosome binding
10 sites, enhancers, regulatory sites (e.g. activator and repressor (operator) sites) and expression elements naturally associated with the α and/or β TcR peptide genes.

15 17. The vector of claim 16 which is a viral vector, being for example based on simian virus 40, adenoviruses (e.g. human adenoviruses), retroviruses, and papillomavirus.

18. The vector of claim 16 or claim 17 further
20 comprising; (a) a positive selectable marker, the marker for example being selected from neomycin phosphotransferase, hygromycin phosphotransferase, xanthineguanine phosphoribosyl transferase, the Herpes simplex virus type 1 thymidine kinase, adenine
25 phosphoribosyltransferase and hypoxanthine

-41-

phosphoribosyltransferase and/or (b) a negative
selectable marker, the marker for example being selected
from Herpes simplex virus type 1 thymidine kinase,
adenine phosphoribosyltransferase, hygromycin
5 phosphotransferase and hypoxanthine
phosphoribosyltransferase.

19. A targeted cytotoxic T lymphocyte (for example, a
targeted cytotoxic T lymphocyte according to any one of
10 claims 1 to 10 or 15) having a TcR comprising
heterologous α and β polypeptides, which heterologous
polypeptides confer on the lymphocyte MHC Class I-
restricted specificity for a target cell, for use in
therapy.

15

20. Use of; (a) the targeted cytotoxic T lymphocyte as
defined in claim 19, or (b) the vector of any one of
claims 16 to 18, for the preparation of a medicament for
use in adoptive immunotherapy.

20

21. The use of claim 20 wherein the adoptive
immunotherapy comprises the steps of;

(a) removing cytotoxic T-lymphocytes from a patient,

25

-42-

(b) transfecting the cytotoxic T lymphocytes removed in step (a) with the vector according to any one of claims 16 to 18 to produce targeted cytotoxic T lymphocytes,

5

(c) reintroducing the targeted cytotoxic T lymphocytes of step (b) into the patient.

22. The use of claim 21 further comprising the step of
10 selectively expanding in tissue culture the cytotoxic T cells removed in step (a) prior to steps (b) and (c).

23. The use of any one of claims 20 to 22 wherein the
15 patient is a cancer patient, an AIDS patient, an individual suffering from an autoimmune disease or an immunosuppressed individual (for example an individual bearing a transplanted organ) suffering an opportunistic infection.

20 24. Use of; (a) the targeted cytotoxic T lymphocyte as defined in claim 19, or (b) the vector of any one of claims 16 to 18, for the preparation of a vaccine for use in immunotherapy or prophylaxis, e.g. for use in the treatment or prophylaxis of AIDS.


25

-43-

25. A vaccine comprising the targeted cytotoxic T lymphocyte according to any one of claims 1 to 10 or 15, for example further comprising a pharmaceutically acceptable excipient.


1 / 3

Fig. 1




2 / 3

FIG. 2



3 / 3

FIG. 3



INTERNATIONAL SEARCH REPORT

International Application No
PC/GB 95/02691

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/10 C12N5/10 C12N15/63 C12N15/85 A61K35/14
A61K39/00 //C07K14/725

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NATURE, vol. 320, 20 March 1986 LONDON, GB, pages 232-238, Z. DEMBIC ET AL. 'Transfer of specificity by murine alpha and beta T-cell receptor genes.' cited in the application see the whole document	1,2,4,9, 11,12, 14-20
Y	--- WO,A,92 12996 (THE IMMUNE RESONSE CORPORATION) 6 August 1992 see page 31, line 1 - page 32, line 16 see claims 99-102,112,113 --- -/--	1-5,9, 11,12, 15,19-23

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

20 February 1996

Date of mailing of the international search report

19.03.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patendaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Nooij, F

INTERNATIONAL SEARCH REPORT

International Application No

PC1/GB 95/02691

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,91 01133 (A. VANDENBARK) 7 February 1991 see claims 43-47	1-5,9, 11,12, 15,19-23
A	--- PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 86, no. 24, December 1989 WASHINGTON, DC, USA, pages 10024-10028, G. GROSS ET AL. 'Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.' see abstract	10
A	--- EP,A,0 180 878 (MASSACHUSETTS INSTITUTE OF TECHNOLOGY) 14 May 1986 see claims	1,9,11, 12,15
A	--- PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 84, May 1987 WASHINGTON, DC, USA, pages 2936-2940, N. GASCOIGNE ET AL. 'Secretion of a chimeric T-cell receptor-immunoglobulin protein.' see abstract -----	10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PC1/GB 95/02691

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9212996	06-08-92	AU-B- 1271692 CA-A- 2101065 EP-A- 0568623 JP-T- 6507384	27-08-92 23-07-92 10-11-93 25-08-94
WO-A-9101133	07-02-91	AU-B- 652540 AU-B- 6048590 CA-A- 2064077 EP-A- 0552142 IL-A- 95125 JP-T- 5504939	01-09-94 22-02-91 20-01-91 28-07-93 31-07-95 29-07-93
EP-A-180878	14-05-86	US-A- 4873190 JP-A- 61257998 US-A- 5189147 US-A- 4970296	10-10-89 15-11-86 23-02-93 13-11-90